{"id":3091,"date":"2016-02-04T07:30:00","date_gmt":"2016-02-04T07:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/report-on-operations-2015\/"},"modified":"2016-02-04T07:30:00","modified_gmt":"2016-02-04T07:30:00","slug":"report-on-operations-2015","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-on-operations-2015\/","title":{"rendered":"Report on operations 2015"},"content":{"rendered":"
Strong sales growth and increased EBITDA<\/strong><\/div>\n<\/p>\n

FOURTH QUARTER 2015 (OCT \u2013 DEC)<\/span><\/p>\n<\/p>\n

\u2022 Net sales in the quarter amounted to SEK 32.7 (25.5) million, corresponding to an increase of 28 percent. Net sales increased by 17 percent in local currency.<\/span>
\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 6.9 (3.1) million, corresponding to an EBITDA margin of 21 percent. <\/span>
\u2022 Net income amounted to SEK 2.8 (0.3) million, resulting in earnings per share of SEK 0.13 (0.01). The figures are affected by amortization and depreciation of SEK 3.1 (2.6) million. <\/span>
\u2022 Cash flow from operating activities was SEK 2.9 (-5.4) million.<\/span>
\u2022 Net sales of non-Durable goods* in the quarter amounted to SEK 29.1 (25.5) million, corresponding to an increase of 14 percent in SEK. Sales of non-Durable goods increased by 5 percent in local currency.<\/span>
\u2022 Products for warm perfusion (STEEN Solution\u2122, the XPS\u2122 and products related to the use of the XPS\u2122) accounted for 40 (34) percent of total product sales. <\/span>
\u2022 Three XPS\u2122 was delivered during the quarter. One to the US and two to Europe, whereof one to the world\u2019s second largest lung transplant clinic in Vienna, Austria.<\/span>
\u2022 The China Food and Drug Administration (CFDA) approved STEEN Solution\u2122 for marketing and clinical use in China.<\/span><\/p>\n<\/p>\n

THE PERIOD 2015 (JAN \u2013 DEC)<\/span><\/p>\n<\/p>\n

\u2022 Net sales in the period amounted to SEK 120.2 (84.7) million, corresponding to an increase of 42 percent. Net sales increased by 25 percent in local currency.<\/span>
\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 18.8 (11.4) million, corresponding to an EBITDA margin of 16 percent. <\/span>
\u2022 Net income amounted to SEK 5.1 (5.2) million, resulting in earnings per share of SEK 0.24 (0.25) after depreciation and amortization of SEK 11.6 (3.9) million had been charged to the period.<\/span>
\u2022 Cash flow from operating activities was SEK 8.6 (-4.6) million.<\/span>
\u2022 Net sales of non-Durable goods* in the period amounted to SEK 106.0 (83.2) million, corresponding to an increase of 27 percent in SEK. Sales of non-Durable goods increased by 12 percent in local currency.<\/span>
\u2022 Products for warm perfusion (STEEN Solution\u2122, the XPS\u2122 and products related to use of the XPS\u2122) accounted for 39 (28) percent of total product sales.<\/span>
\u2022 The first XPS\u2122 was delivered to Europe. During the year a total of 4 clinics in Europe gained access to the XPS\u2122, including the world\u2019s second largest lung transplant clinic in Vienna, Austria.<\/span>
\u2022 The United States Patent and Trademark Office approved a third patent in the \u201cPreservation and evaluation solution\u201d family, which means that STEEN Solution\u2122 and the XPS\u2122 have broader patent protection in the US.<\/span>
\u2022 A strategic decision was made to apply for listing on Nasdaq Stockholm\u2019s main market during 2016.
\u2022 The first liver transplant using STEEN Solution\u2122 was performed in Toronto, Canada, as part of a clinical phase 1 study.<\/span><\/p>\n<\/p>\n

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER<\/span><\/p>\n<\/p>\n

\u2022 A decision was made to apply for listing on the First North Premier segment as one step on the way to preparing the company for an application for listing on NASDAQ Stockholm\u2019s main market.<\/span>
\u2022 The company has obtained a CE mark for a patent-protected product, PrimECC\u00ae<\/sup>, which has been developed to prime heart-lung machines before open heart surgery. The company will expand the clinical documentation for PrimECC\u00ae<\/sup> through more clinical studies in 2016.<\/span>
\u2022 At the time of publication of this report, 23 clinics have access to the XPS\u2122, including 18 clinics in the US and 4 clinics in Europe.<\/span>
\u2022 After the end of the quarter one XPS\u2122 contract was signed in Europe<\/span><\/p>\n<\/p>\n

CONFERENCE CALL<\/span><\/p>\n<\/p>\n

\u00a0CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Thursday, February 4, 2016. Telephone: +44 (0) 1452 555566, enter code 68991296.<\/span><\/p>\n<\/p>\n

February 4, 2016
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO<\/span><\/p>\n<\/p>\n

* Durable goods are sales revenues from the XPS\u2122.<\/span><\/p>\n

\n

For further information please contact:<\/span><\/p>\n

Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
<\/a>Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com<\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/a><\/span><\/p>\n

The information was submitted for publication on\u00a0February 4, 2016\u00a0at 8:30 a.m.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Strong sales growth and increased EBITDA FOURTH QUARTER 2015 (OCT \u2013 DEC) \u2022 Net sales in the quarter amounted to…<\/p>\n","protected":false},"template":"","class_list":["post-3091","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q4"],"acf":[],"yoast_head":"\nReport on operations 2015 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-on-operations-2015\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Report on operations 2015 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Strong sales growth and increased EBITDA FOURTH QUARTER 2015 (OCT \u2013 DEC) \u2022 Net sales in the quarter amounted to...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-on-operations-2015\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-on-operations-2015\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-on-operations-2015\\\/\",\"name\":\"Report on operations 2015 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2016-02-04T07:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-on-operations-2015\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-on-operations-2015\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-on-operations-2015\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Report on operations 2015\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Report on operations 2015 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-on-operations-2015\/","og_locale":"en_US","og_type":"article","og_title":"Report on operations 2015 - XVIVO","og_description":"Strong sales growth and increased EBITDA FOURTH QUARTER 2015 (OCT \u2013 DEC) \u2022 Net sales in the quarter amounted to...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-on-operations-2015\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-on-operations-2015\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-on-operations-2015\/","name":"Report on operations 2015 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2016-02-04T07:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-on-operations-2015\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-on-operations-2015\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-on-operations-2015\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Report on operations 2015"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}